Balchem Corporation (BCPC) Stock Price, News, Quote & History
This article provides a comprehensive overview of Balchem Corporation (BCPC), including its current stock price, historical data, financial performance, and analyst insights. Balchem is a specialty chemicals company operating in human nutrition, animal nutrition, and specialty products markets. The report details the company's financial metrics, earnings trends, and performance relative to the S&P 500.
Balchem: How DNA methylation supports cellular health for life
This Balchem whitepaper explores the critical role of DNA methylation in maintaining cellular health throughout life, from prenatal development to healthy aging. It delves into one-carbon metabolism, identifies nutrient gaps, and highlights the growing market for methyl-donating ingredients. The paper offers a framework for developing science-backed products that support epigenetic health across the human lifespan.
Balchem Corp Revenue Breakdown – HAN:BL9B
Balchem Corp's financial data for the last year shows a total revenue of 883.06 M EUR. The Human Nutrition and Health segment was the top performer, contributing 561.41 M EUR. The United States was the primary regional contributor, accounting for 646.61 M EUR of the revenue.
Net income before discontinued operations of Balchem Corp – HAN:BL9B
This article presents the net income before discontinued operations for Balchem Corp, traded on the Hannover Stock Exchange under the symbol BL9B. It shows a table with the period, value, and change for this financial metric. The content is primarily a financial data point rather than a descriptive analysis.
Most of the shares held directly by Balchem's (BCPC) R&D chief are restricted and vest over time.
Balchem's SVP and Chief R&D Officer, Ren Anthony Gonzalez, reported holdings including 6,335 directly held common shares and 884 indirectly held common shares in a 401(k) Plan as of September 16, 2026. A significant portion of his direct holdings, 6,133 shares, are restricted stock that vests over one to three years. Gonzalez also holds an employee option for 240 common shares with an exercise price of $143.43, exercisable from February 8, 2027.
Balchem Corporation (BCPC) Stock forecasts
Argus has raised its target price for Balchem Corporation (BCPC) to $185.00, up from its current price of $167.84. Balchem Corp specializes in developing, manufacturing, and marketing specialty performance ingredients for various industries. The report was published on September 23, 2026.
Balchem (BCPC) Stock Could Be 25% Undervalued On Cash Flow
Balchem's stock has returned 38.7% over the past three years, prompting a focus on its current valuation against cash flows. A Discounted Cash Flow (DCF) analysis suggests Balchem, with a last twelve-month free cash flow of $177.6m and projected growth, is currently undervalued by about 25% compared to its intrinsic value. While a bull case highlights capacity expansion, a bear case suggests potential risks of underutilized capacity.
Balchem study shows Optifolin+ boosts DNA methylation, boosting link to healthy ageing
A new study led by the University of Arkansas and announced by Balchem found that Optifolin+ significantly enhances cellular methylation capacity and DNA methylation in a human cell model. This research, published in the Journal of Dietary Supplements, provides mechanistic evidence for the choline-enriched L-5-MTHF ingredient's epigenetic activity, strengthening its potential for healthy aging and one-carbon metabolism formulations. The findings highlight Optifolin+'s role in epigenetic regulation by increasing S-adenosylmethionine (SAM) by 71% and enhancing cellular DNA methylation by up to 14 times.
Balchem Corporation to Participate in the 9th Annual Wells Fargo Consumer Conference on September 23, 2026
Balchem Corporation announced its participation in the 9th Annual Wells Fargo Consumer Conference on September 23, 2026. Key executives, including Chairman and CEO Ted Harris, CFO Martin Bengtsson, and Senior Director Investor Relations Allison Baurichter, will represent the company. Balchem specializes in developing and manufacturing specialty ingredients for health and nutrition markets, across human nutrition, animal nutrition, and specialty products segments.
Balchem Corp Revenue Breakdown – BMV:BCPC
Balchem Corp (BMV:BCPC) generated 18.70 billion MXN in revenue last year, with its Human Nutrition and Health segment contributing the most at 11.89 billion MXN. The United States was the largest regional contributor, accounting for 13.69 billion MXN of the company's revenue.
Top tips for keeping up with the protein boom
This article highlights the growing consumer demand for protein, particularly in meat snack sticks, and offers strategies for manufacturers to keep pace. It encourages downloading an infographic from Balchem that explores market drivers, new opportunities from GLP-1 use and better-for-you snacking, and product development strategies. The infographic also details how Balchem’s MeatShure® microencapsulated acids can boost production capacity.
Balchem (BCPC) Q2 Results Raise The Question Of Whether The Stock Is Fully Valued
Balchem (BCPC) recently reported strong Q2 2026 results with higher sales, net income, and EPS, leading to share price momentum. While one valuation narrative suggests the stock is 14.4% undervalued with a fair value of $207, driven by growth in its microencapsulation facility and improved margins, another view highlights potential overvaluation. The company's P/E ratio of 34.3x is higher than the US Chemicals industry (29.4x) and peers (25.7x), indicating valuation risk if sentiment cools.
Did Balchem’s Strong Q2 Results and Completed Buyback Just Shift Balchem's (BCPC) Investment Narrative?
Balchem Corporation (BCPC) reported strong Q2 2026 results with higher sales and net income, alongside completing a share repurchase program worth US$55.49 million. These actions suggest management confidence and improve the company's earnings per share, impacting its investment narrative. While the results are encouraging, investors should still consider risks related to product innovation and tariff exposure.
Balchem Corp (BCPC) Stock News Today
This article provides current news and financial data for Balchem Corp (BCPC), a chemicals company. It highlights recent earnings, specifically Q2 2026 results where all three segments drove an 11.2% sales growth. The page also offers stock performance, analyst ratings, and other key developments for investors.
Balchem (BCPC) Could Be 16% Undervalued As Q2 Results And Buybacks Land
Balchem (BCPC) recently released its Q2 2026 results and provided an update on its share buyback program. The stock is considered 16% undervalued, with a fair value estimated at $207 compared to its current price of $174.78, driven by its new microencapsulation facility and projected sales growth. However, its P/E ratio of 33.9x compared to an industry average of 25x suggests potential valuation risk if market sentiment shifts.
H.C. Wainwright raises Balchem stock price target on strong earnings
H.C. Wainwright has increased its price target for Balchem (NASDAQ:BCPC) to $215 from $190, reiterating a Buy rating, following the company's strong second-quarter 2026 financial results. Balchem reported revenue of $284 million, exceeding estimates, and GAAP net earnings of $1.39 per diluted share, also surpassing forecasts. The firm raised its full-year 2026 revenue and earnings projections, citing Balchem's consistent growth, healthy gross profit margin, and 16 consecutive years of dividend increases.
Balchem (BCPC) Stock Gains Look Muted Next To Record Margins
Balchem (BCPC) reported record quarterly revenue and adjusted earnings, yet its stock only saw a 3% gain. The company's net profit margin is up, and it achieved record adjusted EBITDA, indicating strong profitability trends. Despite a high 34.1x P/E ratio, the earnings quality suggests that the stock's current valuation needs to be further evaluated against its financial health and future growth prospects.
Balchem Corporation Revenue Breakdown – NASDAQ:BCPC
Balchem Corporation (BCPC) generated $1.04 billion USD in revenue last year, with its Human Nutrition and Health segment being the top performer at $659.39 million USD. The United States was the largest contributor to revenue, accounting for $759.45 million USD. These figures highlight the company's key revenue streams and geographic strength.
Q2 2026 Balchem Corp Earnings Call Transcript
Balchem Corp reported record consolidated sales of $284 million, up 11.2% year-over-year, and record adjusted EBITDA of $78 million for Q2 2026. The growth was broad-based across all segments, including significant gains in Animal Nutrition & Health and Specialty Products, while Human Nutrition & Health also saw record sales. Despite higher input costs and operating expenses, the company demonstrated consistent performance with its 28th consecutive quarter of year-over-year growth in adjusted EBITDA and strengthened its financial flexibility through a revolving credit facility refinancing.
Balchem Corporation Reports Record Second Quarter 2026 Net Sales, Earnings and Adjusted EBITDA
Balchem Corporation announced record financial results for the second quarter of 2026, with net sales increasing 11.2% to $284.0 million, net earnings rising 16.6% to $44.6 million, and adjusted EBITDA growing 12.6% to $77.9 million. This strong performance was driven by growth across all three business segments: Human Nutrition and Health, Animal Nutrition and Health, and Specialty Products. The company also amended its credit agreement to increase borrowing capacity and repurchased $29 million of its common stock, demonstrating a commitment to shareholder value.
Balchem Q2 2026: Revenue Hits $284.0M, Up 11% Year-Over-Year
Balchem Corporation (NASDAQ: BCPC) reported strong Q2 2026 results, with adjusted earnings of $1.49 per share beating estimates and revenue reaching $284.0 million, an 11.2% increase year-over-year. The Human Nutrition and Health segment was a key driver, contributing $176.9 million in revenue with 10.0% growth. Despite the positive financial performance, the stock saw a muted market reaction, though analysts generally maintain a constructive view.
Balchem Releases Q2 2026 Financial Results
Balchem Corporation reported strong Q2 2026 financial results, exceeding consensus estimates with adjusted earnings of $1.49 per share and revenue of $284.0 million. The company saw significant growth in its Human Nutrition and Health segment, driven by robust demand for its specialty ingredients. Analysts maintain a favorable outlook on the stock.
Balchem repurchases $29M of stock as Q2 net earnings rise 16.6%
Balchem (NASDAQ: BCPC) announced record financial results for the second quarter of 2026, with net sales increasing 11.2% year-over-year to $284.0 million and GAAP net earnings rising 16.6% to $44.6 million. All three business segments reported higher sales, and the company repurchased $29 million of its common stock during the quarter, reflecting a commitment to shareholder value. Balchem also amended its revolving credit facility, extending its maturity and increasing borrowing capacity to $650 million.
Balchem Reports Q2 2026: Revenue $284.0M, Net Earnings $44.6M, Adjusted EPS $1.49
Balchem reported record financial results for the second quarter of fiscal year 2026, with net sales reaching $284.0 million, an 11.2% increase year-over-year. The company achieved GAAP net earnings of $44.6 million and an adjusted diluted EPS of $1.49. Balchem also generated $36.2 million in free cash flow and repurchased $29 million of stock during the quarter.
Earnings Flash (BCPC) Balchem Corporation Posts Q2 Adjusted EPS $1.49 per Share, Vs. FactSet Est of $1.40
Balchem Corporation (BCPC) reported strong Q2 adjusted earnings per share of $1.49, surpassing the FactSet estimate of $1.40. This announcement provides key financial data for investors and analysts tracking the company's performance. The detailed earnings flash highlights the company's profitability during the quarter.
Balchem Corporation Reports Second Quarter 2026 Financial Results
Balchem Corporation reported strong financial results for its second quarter ended June 30, 2026, with record net sales of $284.0 million, a 11.2% increase from the prior year. All three reporting segments—Human Nutrition and Health, Animal Nutrition and Health, and Specialty Products—showed healthy growth. The company also amended its credit agreement to increase borrowing capacity and repurchased $29 million of common stock, reflecting confidence in future growth.
Balchem Corporation Reports Second Quarter 2026 Financial Results
Balchem Corporation announced strong financial results for the second quarter of 2026, reporting record net sales, net earnings, and adjusted EBITDA. All three reporting segments—Human Nutrition and Health, Animal Nutrition and Health, and Specialty Products—showed healthy growth. The company also highlighted a recent credit agreement amendment that increased borrowing capacity and discussed its ongoing share repurchase program.
ETFs Investing in Balchem Corp Stocks
This article lists various ETFs that include Balchem Corp (BL9B) stocks in their holdings. The information provided for each ETF includes market value, weight, issuer, management style, focus, expense ratio, assets under management (AUM), current price and change, relative volume, and 3-year NAV total return. The ETFs predominantly focus on small-cap and extended market segments, with BlackRock, Vanguard, and First Trust being prominent issuers.
Balchem Corp (BCPC) Financial Health: Profitability & Balance Sheet Analysis
Balchem Corp (BCPC) has a robust financial score of 9.04, ranking 6th out of 65 in the Chemicals industry, indicating strong financial health and high operating efficiency. The company recently reported a quarterly revenue of $270.71 million, an 8.06% year-over-year increase, with net profit rising by 8.72% year-over-year. While specific detailed financial data are not yet disclosed, the overall indicators point to positive growth potential and shareholder returns.
BALCHEM CORP 2026: Revenue $284M, EPS $1.39— 10-Q Summary
BALCHEM CORP (BCPC) reported strong second-quarter 2026 results with revenue of $284 million, net income of $44.62 million, and diluted EPS of $1.39, all surpassing prior-year figures. This growth was broad-based across all segments, driven by increased volume, improved mix, and higher selling prices, particularly in animal nutrition. The company also noted gross margin expansion due to manufacturing efficiencies and ongoing investments in technology and capacity.
Balchem Number of Employees 2026 | Employee Count & Headcount Data
Balchem Corp. (BCPC) had approximately 1,353 employees worldwide as of March 2026, a 2.4% growth from 2023. The company is actively hiring with 107 active job postings in 2026 and its workforce is concentrated in the United States, followed by Italy and Norway. While overall employee sentiment is neutral, it has been declining year over year.
BCPC|Balchem Corp|Price:162.040|Chg%:-1.670
Balchem Corp (BCPC) is currently priced at $162.85, showing a slight decrease of 0.53%. The company's fundamentals are strong with high growth potential, and its valuation is considered fair within the Chemicals industry. Analysts have rated BCPC as a "Buy" with a target price of $200.75, indicating a 21.82% upside, and institutional ownership remains very high despite a recent decrease in holdings.
Balchem Corp (BCPC) Institutional Confidence
This article analyzes Balchem Corp's (BCPC) institutional confidence score, reporting it at 7.00, which ranks 28th out of 65 in the Chemicals industry. The institutional shareholding proportion is 88.34%, marking a quarter-over-quarter decrease of 4.74%. The largest institutional shareholder, ETHSX, significantly increased its holdings to 2.07% of shares outstanding.
How Balchem Corporation (BCPC) Affects Rotational Strategy Timing
Balchem Corporation (BCPC) is exhibiting a mid-channel oscillation pattern with strong near-term sentiment but neutral mid and long-term outlooks. AI models have generated three distinct trading strategies: a position trading strategy, a momentum breakout strategy, and a risk hedging strategy, each tailored to different risk profiles. The stock also presents an exceptional risk-reward short setup targeting a 6.6% downside.
Balchem Corp Revenue Breakdown – BX:BL9B
Balchem Corp's revenue last year was 822.23 M CHF. The Human Nutrition and Health segment was the top-performing segment, generating 522.74 M CHF. The United States contributed the most geographically, accounting for 602.07 M CHF of the revenue.
Balchem Corporation (NASDAQ: BCPC) boosts revolving credit to $650M and 2031
Balchem Corporation amended its credit agreement on July 24, 2026, increasing its revolving commitment from $550 million to $650 million and extending the maturity date to July 24, 2031. The amendment also allows foreign subsidiary Balchem B.V. to borrow, eliminates a 10 basis point SOFR adjustment, and reduces applicable margins for loans at higher leverage levels, thereby lowering borrowing costs. These changes provide Balchem with greater financial flexibility and expanded liquidity.
Balchem Corp (BCPC) Cash Flow
This article provides a detailed cash flow statement for Balchem Corp (BCPC), broken down by quarterly and annual periods. It covers operating, investing, and financing cash flows, along with related metrics like net income and capital expenditures. The report also includes an FAQ section explaining key cash flow concepts and Balchem Corp's performance in these areas.
Balchem Corp (BCPC) Earnings Forecast: Future EPS & Revenue Growth Estimates
This article provides an earnings forecast for Balchem Corp (BCPC), noting its current earnings forecast score of 7.33, ranking 33rd in the Chemicals industry. Analysts have assigned an average price target of $191.00, with a "Buy" trend based on ratings from 3 analysts. Key financial expectations include an anticipated revenue of $268.50M for the next quarter and an expected EPS of $1.40.
Balchem (BCPC) Q2 2026 Preview: EPS Est. $1.43, Reports July 31
Balchem Corporation (BCPC) is expected to report Q2 2026 earnings per share of $1.43 on revenue of $268.5 million on July 31, according to two analysts. This represents a 12.6% increase in EPS and 5.1% growth in revenue year-over-year. Investors will be closely watching management's commentary on pricing, input costs, demand trends, and updated full-year guidance, especially after the company missed estimates in the most recent quarter.
Balchem Ups Revolving Credit Facility to $650 Million and Extends Maturity to 2031 With JPMorgan
Balchem recently amended its credit facility, increasing its revolving commitments to $650 million and extending the maturity date to July 24, 2031. This amendment, facilitated with JPMorgan Chase and a syndicate of lenders, also allows foreign subsidiary borrowing, removes a SOFR adjustment, and reduces margins at higher leverage tiers. The company anticipates these changes will improve liquidity, lower borrowing costs, and provide greater flexibility for its global operations.
Vitamin K2 Market Projected to Reach $339.9 million by 2031 | Top Companies are Gnosis by Lesaffre (France) and Balchem Corp (US)
The Vitamin K2 market is projected to grow from USD 175.0 million in 2024 to USD 339.9 million by 2031, at a CAGR of 13.5%. This growth is driven by increasing consumer awareness of Vitamin K2's benefits for bone and cardiovascular health. Asia Pacific is expected to be the fastest-growing region, largely due to its aging population and rising demand for health supplements.
TradingKey
This article provides a detailed historical income statement for Balchem Corp (BCPC), displaying quarterly and annual data from FY2012Q1 through FY2026Q1. It includes various financial metrics such as total revenue, cost of revenue, operating expenses, operating profit, income before tax, net income, and earnings per share. The content also features an FAQ section clarifying how to read an income statement and defining key financial terms.
BCPC|Balchem Corp|Price:162.810|Chg%:+1.810
This article provides a detailed analysis of Balchem Corp (BCPC), highlighting its strong fundamentals, high growth potential, and fair valuation within the Chemicals industry. It notes a high institutional ownership and suggests the stock is suitable for range-bound swing trading due to its sideways price movement. The report also details Balchem Corp's segments, financial strengths like high profit growth and stable dividends, and analyst ratings, indicating a "Buy" with a target price of $200.75.
BCPC|Balchem Corp|Price:162.810|Chg%:+1.810
Balchem Corporation (BCPC) is trading at $162.810, up 1.12%. The company specializes in developing and marketing performance ingredients for various markets including nutrition, food, pharmaceuticals, and animal health. Balchem's segments include Human Nutrition and Health, Animal Nutrition and Health, and Specialty Products.
Balchem Corp Revenue Breakdown – BIVA:BCPC
This article provides a revenue breakdown for Balchem Corp (BCPC), highlighting its top-performing segment and geographical contribution. Last year, the company generated 18.70 billion Mexican Pesos (MXN) in total revenue, with Human Nutrition and Health contributing 11.89 billion MXN, and the United States being the largest regional contributor with 13.69 billion MXN.
Vitamin K2 Market Projected to Reach $339.9 million by 2031 | Top Companies are Gnosis by Lesaffre (France) and Balchem Corp (US)
The Vitamin K2 market is forecast to grow from USD 179.0 million in 2026 to USD 339.9 million by 2031, at a CAGR of 13.7%. This growth is driven by increasing consumer awareness regarding its benefits for bone and cardiovascular health, coupled with a rising demand for preventive healthcare and healthy aging solutions. Key players in this market include Gnosis by Lesaffre, Balchem Corp., and Novonesis A/S, with the Asia Pacific region expected to exhibit the fastest growth.
Balchem Corp (BCPC) Valuation: PE, PB & Fair Value Analysis
This article provides a valuation analysis of Balchem Corp (BCPC), noting its current valuation score of 6.27, which ranks 62 out of 65 in the Chemicals industry. The P/E ratio is currently 33.10. The article also indicates that relevant data for P/B, P/S, and P/CF ratios have not yet been disclosed by the company.
Balchem Corporation (BCPC) Stock Forecasts
This article provides a stock forecast for Balchem Corporation (BCPC), noting that Argus has lowered its target price to $148.00. Balchem Corp is described as a company that develops, manufactures, and markets specialty performance ingredients and products for various industries. The report also highlights the current stock price and offers related research reports for other companies.
Balchem (BCPC) Q3 2024 Earnings Report - Results, Call & Slides
Balchem (BCPC) reported its Q3 2024 earnings, missing both EPS and revenue expectations. The company posted an actual EPS of $18.03 against a consensus of $19.52, and actual revenue of $4.20 billion compared to an expected $4.24 billion, though revenue did show a 4.35% year-over-year growth. The earnings call took place on October 25, 2024, and the next earnings date is estimated for October 23, 2026.
Balchem Renews Linus Pauling Institute Partnership to Advance Iron and Epigenetic Health Education
Balchem Corporation has renewed its partnership with Oregon State University's Linus Pauling Institute (LPI) to support education on iron nutrition and epigenetic health through LPI's Micronutrient Information Center (MIC). This collaboration addresses growing consumer interest in healthy aging, DNA methylation, and health span, with the global epigenetics sector projected to reach $14 billion by 2031. Balchem emphasizes the role of its branded ingredients, like Optifolin+, VitaCholine, and OptiMSM, as methyl donors supporting epigenetic processes and gene expression.
